Sexual function of patients with schizophrenia receiving first-generation (FGA) or second-generation antipsychotic (SGA) treatment

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Objectives. The aim of the study was to investigate sexual function in patients with schizophrenia receiving treatment with a first-generation antipsychotic (FGA) or a second-generation antipsychotic (SGA) drug. Sexual function is an important aspect of human experience, which can be affected by antipsychotic drug treatment. Sexual dysfunction in patients with schizophrenia may be less prevalent with SGA than with FGA drug treatment. Methods. A cross-sectional prevalence study assessed sexual function in a sample of 144 patients with DSM-IV schizophrenia aged between 18 and 65, using the Derogatis Interview for Sexual Functioning (self-report version: DISF-SR). Two equal-sized groups (N = 72) received treatment with an FGA or an SGA drug for at least 12 weeks. Results. No significant differences were seen on DISF-SR total score or subscale score between the two treatment groups. Conclusions. There are no differences in measured sexual function of non-randomised patients with schizophrenia treated with an FGA compared with SGA-treated patients. © 2012 Informa Healthcare.
    Original languageEnglish
    Pages (from-to)148-152
    Number of pages4
    JournalInternational Journal of Psychiatry in Clinical Practice
    Volume16
    Issue number2
    DOIs
    Publication statusPublished - Jun 2012

    Keywords

    • Antipsychotic drugs
    • Antipsychotic treatment
    • Atypical drugs
    • Schizophrenia
    • Sexual dysfunction

    Fingerprint

    Dive into the research topics of 'Sexual function of patients with schizophrenia receiving first-generation (FGA) or second-generation antipsychotic (SGA) treatment'. Together they form a unique fingerprint.

    Cite this